Linde plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated July 26, 2019, details the results of the Annual General Meeting (AGM) of shareholders for Linde plc. The meeting was held on July 26, 2019, with 428,237,560 shares present or represented by proxy, constituting 78.87% of outstanding shares and a valid quorum.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders voted on five primary proposals with the following outcomes:
- Proposal 1 (Election of Directors): All twelve nominees were elected. Eleven directors received over 97% of votes cast. Prof. Dr. Martin H. Richenhagen received the lowest support at 68.79% (283,394,169 votes for, 128,550,429 votes against).
- Proposal 2a (Auditor Ratification): Shareholders ratified the appointment of PricewaterhouseCoopers (PWC) as independent auditor with 97.02% of votes cast in favor.
- Proposal 2b (Auditor Remuneration): Shareholders approved the Board's authority to determine PWC's remuneration with 99.07% of votes cast in favor.
- Proposal 3 (Treasury Shares): Shareholders approved the price range for re-allotting treasury shares with 98.93% of votes cast in favor.
- Proposal 4 (Executive Compensation): The advisory vote on Named Executive Officer compensation passed with 91.12% of votes cast in favor.
- Proposal 5 (Frequency of Say-on-Pay): Shareholders recommended annual advisory votes on executive compensation. 98.9% of votes cast favored a 1-year frequency.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. The Board determined, based on the results of Proposal 5, that future advisory votes on executive compensation will be held annually.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Against" votes (approx. 31%) cast for director nominee Prof. Dr. Martin H. Richenhagen compared to other nominees.
- Confirm the specific price range parameters approved under Proposal 3 for the re-allotment of treasury shares, as the filing references the 2019 proxy statement for details.
- Review the 2019 proxy statement for the full disclosure of Named Executive Officer compensation referenced in Proposal 4.